Liquid Biopsy Market Outlook: Growth Fueled by Non-Invasive Cancer Diagnostics

The global liquid biopsy market was valued at USD 10.99 billion in 2024 and is projected to reach USD 28.84 billion by 2033, growing at a CAGR of 11.32% (2025–2033). This surge is driven by the growing preference for non-invasive diagnostic procedures, rapid technological advancements, and increased government spending on healthcare facilities.

👉 Download Sample Report

Market Highlights

• North America held the dominant share with 54.43% of the global market in 2024, supported by advanced healthcare infrastructure and high adoption rates.

• By product and services, the kits and reagents segment led the market in 2024 and is forecasted to grow at a CAGR of 21.2%.

• Based on biomarkers, the circulating tumor cell (CTC) segment accounted for the largest share, expanding at a CAGR of 21% during the forecast period.

• By cancer type, lung cancer contributed the highest revenue, growing at a CAGR of 20.4%, driven by the rising prevalence of non-small cell lung cancer (NSCLC).

• Europe is the second-largest market, while Asia Pacific is set to be the fastest-growing region due to rising awareness, increasing cancer incidence, and improved healthcare infrastructure.

Why the Market is Growing
The rise in cancer cases worldwide and the preference for minimally invasive solutions are accelerating the adoption of liquid biopsy. Compared to traditional methods like CT or PET scans, liquid biopsies are cost-effective, safer, and allow frequent monitoring. These benefits, along with government-backed healthcare spending, are strengthening the market outlook.

Key Market Opportunities
An important opportunity lies in the treatment of rare cancers such as adenocarcinomas and angiosarcomas. With early detection being crucial for survival, liquid biopsy is emerging as a valuable tool where other diagnostic methods fall short.

Regional Insights

• North America: Largest revenue contributor, growing at a CAGR of 20.6%, led by advanced cancer diagnostics adoption.

• Europe: Second-largest market with strong research activity and healthcare support.

• Asia Pacific: Expected to record the fastest growth due to rising cancer cases, large patient base, and growing adoption of advanced diagnostics.

Market Segmentation

• By Product and Services: Kits and Reagents, Platforms and Instruments, Services

• By Circulating Biomarker: Circulating Tumor Cells, Circulating Tumor DNA (ctDNA), Extracellular Vesicles

• By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer

• By End-User: Hospitals and Laboratories, Government and Academic Research Centers

Key Players

• Bio-Rad Laboratories Inc.

• Biocept Inc.

• Guardant Health Inc.

• Illumina Inc.

• Hoffmann-La Roche Ltd. (Foundation Medicine Inc.)

• Johnson & Johnson

• Laboratory Corporation of America Holdings

• Mdxhealth SA

• Qiagen N.V.

• Thermo Fisher Scientific Inc.

Recent Developments

• Feb 2023: Guardant Health’s Guardant360® CDx blood test gained UnitedHealthcare coverage for advanced lung and breast cancer.

• Jan 2023: Janssen’s CARVYKTI® achieved success in Phase 3 trials for multiple myeloma treatment.

• Feb 2023: Element Biosciences partnered with Bio-Rad to streamline RNA sequencing workflows.

About Us:
Straits Research is a leading global market intelligence and consulting firm, dedicated to delivering actionable insights and in-depth analysis across a wide range of industries. Our mission is to empower organizations, investors, and decision-makers with reliable data, strategic guidance, and forward-looking perspectives to help them thrive in a rapidly evolving business landscape.

Contact Us:
Email: sales@straitsresearch.com
Tel: +1 646 905 0080 (U.S.), +44 203 695 0070 (U.K.)
Website: https://straitsresearch.com/